Skip to content
DraconiticResearch
Search Sources API
220,595 studies31 sourcesUpdated 24 min ago
Peer-reviewedCC BY-NC-ND 4.0NPJ Vaccines

Single-cell technologies in mRNA cancer vaccines

  • Ekaterina V. Ovcharenko1
  • Marina R. Patysheva1
  • Kirill M. Kirilenko1
  • Arina A. Ibragimova1
  • Evgeny V. Denisov1,2
  1. 1Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia
  2. 2Research Institute of Molecular and Cellular Medicine, Peoples’ Friendship University of Russia (RUDN University), Moscow, Russia
Read full textPDFDOICite

Abstract

The fast evolution of mRNA-based cancer therapeutics requires advanced frameworks to overcome the challenges of tumor heterogeneity and the immunosuppressive tumor immune microenvironment. In this context, single-cell technologies enable characterization of immune cell subsets, intercellular communication, and therapy resistance drivers. The shift to single-cell profiling provides a transition toward the development of precision mRNA treatments tailored to the unique dynamics of an individual tumor.

Related

  1. mRNA-based cancer vaccines for cancer immunotherapy: current progress, challenges, and emerging opportunities
    Shweta Kulshreshtha, Umesh Kumar, V. V. Sathibabu Uddandrao +3
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Pharmacology & toxicologyFrontiersCrossref
  2. T-cell recognition of SARS-CoV-2 antigen peptides following booster vaccination with mRNA and viral-vectored COVID-19 vaccines
    Adams Kiplimo Maru, Precious Kwesi Kumi, Abigail Naa Adjorkor Pobee +14
    Frontiers in cellular and infection microbiologyPeer-reviewedCC BYFull textInfectious diseaseEurope PMCPMCEurope PMC
  3. Two mRNA Platforms for Canine Rabies Vaccines: Advances, Limitations, and Field Application Prospects
    Xi Wang, Shaozong Guo, Youheng Jiang +4
    China CDC weeklyPeer-reviewedCC BY-NCFull textGeneral medicineEurope PMC
  4. Exploring the potential of mRNA vaccines in combatting communicable and non-communicable diseases in low-income and lower-middle-income countries
    Faida Paison, Queen Ntumurize, Gustave Munyurangabo +11
    Annals of medicine and surgery (2012)Peer-reviewedCC BY-NDFull textGeneral medicineEurope PMC
  5. Development of mRNA vaccines against herpes zoster.
    Dongdong Li, Jun Luo, Junwei Wang +7
    Human vaccines & immunotherapeuticsPeer-reviewedCC BY-NCFull textEpidemiology & public healthEurope PMC

Cite

BibTeXRIS
BibTeX
@article{ovcharenko2026singlecell,
  title = {{Single-cell technologies in mRNA cancer vaccines}},
  author = {Ekaterina V. Ovcharenko and Marina R. Patysheva and Kirill M. Kirilenko and Arina A. Ibragimova and Evgeny V. Denisov},
  journal = {NPJ Vaccines},
  year = {2026},
  month = jul,
  doi = {10.1038/s41541-026-01529-2},
  url = {https://doi.org/10.1038/s41541-026-01529-2},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Single-cell technologies in mRNA cancer vaccines
AU  - Ekaterina V. Ovcharenko
AU  - Marina R. Patysheva
AU  - Kirill M. Kirilenko
AU  - Arina A. Ibragimova
AU  - Evgeny V. Denisov
PY  - 2026
DA  - 2026/07/18
JO  - NPJ Vaccines
DO  - 10.1038/s41541-026-01529-2
UR  - https://doi.org/10.1038/s41541-026-01529-2
AB  - The fast evolution of mRNA-based cancer therapeutics requires advanced frameworks to overcome the challenges of tumor heterogeneity and the immunosuppressive tumor immune microenvironment. In this context, single-cell technologies enable characterization of immune cell subsets, intercellular communication, and therapy resistance drivers. The shift to single-cell profiling provides a transition toward the development of precision mRNA treatments tailored to the unique dynamics of an individual tumor.
SN  - 2059-0105
ER  -